AMGN•benzinga•
Reported Saturday, Amgen And Kyowa Kirin's Rocatinlimab Delivers Up To 42.3% EASI-75 Response At Week 24 In Phase 3 IGNITE Trial
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 10, 2025 by benzinga